1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global CAR-T Cell Therapy Market
2.2. Global CAR-T Cell Therapy Market, By Antigen Type, 2023 (US$ Million)
2.3. Global CAR-T Cell Therapy Market, By  Indication, 2023 (US$ Million)
2.4. Global CAR-T Cell Therapy Market, By Geography, 2023 (US$ Million)
2.5. Attractive Investment Proposition by Geography, 2023

3. CAR-T Cell Therapy Market: Competitive Analysis
3.1. Market Positioning of Key CAR-T Cell Therapy Market Vendors
3.2. Strategies Adopted by CAR-T Cell Therapy Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2023 Versus 2032

4. CAR-T Cell Therapy Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global CAR-T Cell Therapy Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape

5. CAR-T Cell Therapy Market: By Antigen Type, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. CD 19
5.3.2. Pipeline Analysis (Qualitative Analysis)
5.3.2.1. CD 20
5.3.2.2. CD 22
5.3.2.3. CD 30
5.3.2.4. CD 33
5.3.2.5. GD 2
5.3.2.6. HER 2
5.3.2.7. MESO
5.3.2.8. EGFRvIII

6. CAR-T Cell Therapy Market: By  Indication, 2022-2032, USD (Million)
6.1. Market Overview
6.2. Growth & Revenue Analysis: 2023 Versus 2032
6.3. Market Segmentation
6.3.1. Non-Hodgkin’s Lymphoma
6.3.2. Acute Lymphocytic Leukemia
6.3.3. Chronic Lymphocytic Leukemia


7. North America CAR-T Cell Therapy Market, 2022-2032, USD (Million)
7.1. Market Overview
7.2. CAR-T Cell Therapy Market: By Antigen Type, 2022-2032, USD (Million)
7.3. CAR-T Cell Therapy Market: By  Indication, 2022-2032, USD (Million)
7.4.CAR-T Cell Therapy Market: By Region, 2022-2032, USD (Million)
7.4.1.North America
7.4.1.1. U.S.
7.4.1.1.1. CAR-T Cell Therapy Market: By Antigen Type, 2022-2032, USD (Million)
7.4.1.1.2. CAR-T Cell Therapy Market: By  Indication, 2022-2032, USD (Million)
7.4.1.2. Canada
7.4.1.2.1. CAR-T Cell Therapy Market: By Antigen Type, 2022-2032, USD (Million)
7.4.1.2.2. CAR-T Cell Therapy Market: By  Indication, 2022-2032, USD (Million)
7.4.1.3. Rest of North America
7.4.1.3.1. CAR-T Cell Therapy Market: By Antigen Type, 2022-2032, USD (Million)
7.4.1.3.2. CAR-T Cell Therapy Market: By  Indication, 2022-2032, USD (Million)

8. UK and European Union CAR-T Cell Therapy Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. CAR-T Cell Therapy Market: By Antigen Type, 2022-2032, USD (Million)
8.3. CAR-T Cell Therapy Market: By  Indication, 2022-2032, USD (Million)
8.4.CAR-T Cell Therapy Market: By Region, 2022-2032, USD (Million)
8.4.1.UK and European Union
8.4.1.1. UK
8.4.1.1.1. CAR-T Cell Therapy Market: By Antigen Type, 2022-2032, USD (Million)
8.4.1.1.2. CAR-T Cell Therapy Market: By  Indication, 2022-2032, USD (Million)
8.4.1.2. Germany
8.4.1.2.1. CAR-T Cell Therapy Market: By Antigen Type, 2022-2032, USD (Million)
8.4.1.2.2. CAR-T Cell Therapy Market: By  Indication, 2022-2032, USD (Million)
8.4.1.3. Spain
8.4.1.3.1. CAR-T Cell Therapy Market: By Antigen Type, 2022-2032, USD (Million)
8.4.1.3.2. CAR-T Cell Therapy Market: By  Indication, 2022-2032, USD (Million)
8.4.1.4. Italy
8.4.1.4.1. CAR-T Cell Therapy Market: By Antigen Type, 2022-2032, USD (Million)
8.4.1.4.2. CAR-T Cell Therapy Market: By  Indication, 2022-2032, USD (Million)
8.4.1.5. France
8.4.1.5.1. CAR-T Cell Therapy Market: By Antigen Type, 2022-2032, USD (Million)
8.4.1.5.2. CAR-T Cell Therapy Market: By  Indication, 2022-2032, USD (Million)
8.4.1.6. Rest of Europe
8.4.1.6.1. CAR-T Cell Therapy Market: By Antigen Type, 2022-2032, USD (Million)
8.4.1.6.2. CAR-T Cell Therapy Market: By  Indication, 2022-2032, USD (Million)

9. Asia Pacific CAR-T Cell Therapy Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. CAR-T Cell Therapy Market: By Antigen Type, 2022-2032, USD (Million)
9.3. CAR-T Cell Therapy Market: By  Indication, 2022-2032, USD (Million)
9.4.CAR-T Cell Therapy Market: By Region, 2022-2032, USD (Million)
9.4.1.Asia Pacific
9.4.1.1. China
9.4.1.1.1. CAR-T Cell Therapy Market: By Antigen Type, 2022-2032, USD (Million)
9.4.1.1.2. CAR-T Cell Therapy Market: By  Indication, 2022-2032, USD (Million)
9.4.1.2. Japan
9.4.1.2.1. CAR-T Cell Therapy Market: By Antigen Type, 2022-2032, USD (Million)
9.4.1.2.2. CAR-T Cell Therapy Market: By  Indication, 2022-2032, USD (Million)
9.4.1.3. India
9.4.1.3.1. CAR-T Cell Therapy Market: By Antigen Type, 2022-2032, USD (Million)
9.4.1.3.2. CAR-T Cell Therapy Market: By  Indication, 2022-2032, USD (Million)
9.4.1.4. Australia
9.4.1.4.1. CAR-T Cell Therapy Market: By Antigen Type, 2022-2032, USD (Million)
9.4.1.4.2. CAR-T Cell Therapy Market: By  Indication, 2022-2032, USD (Million)
9.4.1.5. South Korea
9.4.1.5.1. CAR-T Cell Therapy Market: By Antigen Type, 2022-2032, USD (Million)
9.4.1.5.2. CAR-T Cell Therapy Market: By  Indication, 2022-2032, USD (Million)
9.4.1.6. Rest of Asia Pacific
9.4.1.6.1. CAR-T Cell Therapy Market: By Antigen Type, 2022-2032, USD (Million)
9.4.1.6.2. CAR-T Cell Therapy Market: By  Indication, 2022-2032, USD (Million)

10. Latin America CAR-T Cell Therapy Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. CAR-T Cell Therapy Market: By Antigen Type, 2022-2032, USD (Million)
10.3. CAR-T Cell Therapy Market: By  Indication, 2022-2032, USD (Million)
10.4.CAR-T Cell Therapy Market: By Region, 2022-2032, USD (Million)
10.4.1.Latin America
10.4.1.1. Brazil
10.4.1.1.1. CAR-T Cell Therapy Market: By Antigen Type, 2022-2032, USD (Million)
10.4.1.1.2. CAR-T Cell Therapy Market: By  Indication, 2022-2032, USD (Million)
10.4.1.2. Mexico
10.4.1.2.1. CAR-T Cell Therapy Market: By Antigen Type, 2022-2032, USD (Million)
10.4.1.2.2. CAR-T Cell Therapy Market: By  Indication, 2022-2032, USD (Million)
10.4.1.3. Rest of Latin America
10.4.1.3.1. CAR-T Cell Therapy Market: By Antigen Type, 2022-2032, USD (Million)
10.4.1.3.2. CAR-T Cell Therapy Market: By  Indication, 2022-2032, USD (Million)

11. Middle East and Africa CAR-T Cell Therapy Market, 2022-2032, USD (Million)
11.1. Market Overview
11.2. CAR-T Cell Therapy Market: By Antigen Type, 2022-2032, USD (Million)
11.3. CAR-T Cell Therapy Market: By  Indication, 2022-2032, USD (Million)
11.4.CAR-T Cell Therapy Market: By Region, 2022-2032, USD (Million)
11.4.1.Middle East and Africa
11.4.1.1. GCC
11.4.1.1.1. CAR-T Cell Therapy Market: By Antigen Type, 2022-2032, USD (Million)
11.4.1.1.2. CAR-T Cell Therapy Market: By  Indication, 2022-2032, USD (Million)
11.4.1.2. Africa
11.4.1.2.1. CAR-T Cell Therapy Market: By Antigen Type, 2022-2032, USD (Million)
11.4.1.2.2. CAR-T Cell Therapy Market: By  Indication, 2022-2032, USD (Million)
11.4.1.3. Rest of Middle East and Africa
11.4.1.3.1. CAR-T Cell Therapy Market: By Antigen Type, 2022-2032, USD (Million)
11.4.1.3.2. CAR-T Cell Therapy Market: By  Indication, 2022-2032, USD (Million)

12. Company Profile
12.1. Bellicum Pharmaceuticals, Inc.
12.1.1. Company Overview
12.1.2. Financial Performance
12.1.3. Product Portfolio
12.1.4. Strategic Initiatives
12.2. Celgene Corporation
12.2.1. Company Overview
12.2.2. Financial Performance
12.2.3. Product Portfolio
12.2.4. Strategic Initiatives
12.3. Cellectis
12.3.1. Company Overview
12.3.2. Financial Performance
12.3.3. Product Portfolio
12.3.4. Strategic Initiatives
12.4. Eureka Therapeutics, Inc.
12.4.1. Company Overview
12.4.2. Financial Performance
12.4.3. Product Portfolio
12.4.4. Strategic Initiatives
12.5. Immune Therapeutics, Inc.
12.5.1. Company Overview
12.5.2. Financial Performance
12.5.3. Product Portfolio
12.5.4. Strategic Initiatives
12.6. Gilead Sciences, Inc.
12.6.1. Company Overview
12.6.2. Financial Performance
12.6.3. Product Portfolio
12.6.4. Strategic Initiatives
12.7. Novartis AG
12.7.1. Company Overview
12.7.2. Financial Performance
12.7.3. Product Portfolio
12.7.4. Strategic Initiatives
12.8. Sorrento Therapeutics, Inc.
12.8.1. Company Overview
12.8.2. Financial Performance
12.8.3. Product Portfolio
12.8.4. Strategic Initiatives